• Alan Carter has been named VP of global business development at Agendia (Amsterdam, The Netherlands). Carter will assume responsibility for strategic business opportunities to build on the current success of Agendia's molecular diagnostics portfolio.

• Joseph Blanchard has been appointed COO of Aushon BioSystems (Billerica, Massachusetts), a provider of advanced microarray instrumentation and laboratory services for biomarker analysis. Blanchard joins the company from Decision Biomarkers, where he served as senior VP of business development and strategy.

• Paul Krell has been named CEO of CNSystems (Graz, Austria), joining the company from from Abiomed Europe, where he served as general manager for Europe. Krell replaces J rgen Fortin, a CNSystems founder and CEO since the firm began in 1998. Fortin will continue with the company as chief scientific officer and will focus on expanding the company's technology portfolio and identifying new markets for its products. CNSystems markets CNAP, the first continuous, non-invasive blood pressure management system ready for day-to-day clinical use.

• NMT Medical (Boston) said Frank Martin, a director of the company, has been appointed interim president/CEO, assuming the responsibilities formerly held by John Ahern. Ahern reported his retirement and has also resigned from his position as a director of the company. NMT's board said it has begun the search for a permanent CEO and has retained an executive recruiting firm. NMT also reported that Richard Davis, its current executive VP/CFO, was promoted to the newly created position of COO. Davis will retain the CFO role. NMT develops implant technologies for interventional cardiologists to treat structural heart disease.